Last updated: February 16, 2026
Product Overview
NDC 00591-4104 is an injectable form of botulinum toxin marketed as Daxxify (formerly known as DaxibotulinumtoxinA-Lanm). The product is used for the treatment of glabellar lines (frown lines) in adults. It is developed by Revance Therapeutics Inc., approved by the FDA in September 2022. Daxxify holds a unique position as a longer-acting botulinum toxin, with a duration of effect ranging up to six months or more, compared to Botox and other competitors, which typically last 3-4 months.
Market Landscape
1. Market Size & Growth
- The global botulinum toxin market was valued at approximately USD 4.2 billion in 2022.
- The segment for neurotoxin treatments for aesthetic indications accounts for roughly 70%, with non-aesthetic uses making up the remaining 30%.
2. Key Competitors
- Botox (onabotulinumtoxinA) by Allergan (AbbVie): Dominates with over 50% market share.
- Dysport (abobotulinumtoxinA) by Ipsen/Medicis.
- Xeomin (incobotulinumtoxinA) by Merz.
- Jeuveau (prabotulinumtoxinA-xvfs) by Evolus.
- Other emerging long-acting formulations
3. Differentiation & Positioning
- Daxxify's proposed advantage lies in its longer duration, reducing treatment frequency.
- Clinical trials demonstrated efficacy lasting at least 6 months in most patients, with some extending beyond 8 months.
4. Launch and Adoption Factors
- Approval occurred late 2022; initial sales targeted high-volume aesthetic clinics.
- Physician adoption depends on efficacy confirmation, safety profile, and insurance reimbursement pathways.
- Pricing strategies will influence market penetration and competitive positioning.
Pricing Strategy and Projection
1. Current Pricing
- For Botox, average retail price is approximately USD 530–560 per 100 units, with typical dosing for glabellar lines around 20–40 units, translating to USD 100–200 per treatment.
- Daxxify, with a longer action duration, is expected to command a premium price. Early market reports and analyst estimates suggest USD 600–700 per treatment.
2. Price Tiers and Willingness to Pay
- Long-acting formulations similar to Daxxify tend to be priced 10–30% higher than Botox per treatment cycle.
- Physicians may coordinate payment strategies based on reimbursement codes and patient willingness to pay out-of-pocket.
3. Revenue Projections
| Year |
Units Sold (millions) |
Revenue (USD billions) |
Assumptions |
| 2023 |
2 |
1.4 |
Early adoption, cautious penetration |
| 2024 |
5 |
3.5 |
Increased adoption, expanding clinician base |
| 2025 |
10 |
7.0 |
Widespread acceptance, stable pricing |
| 2026 |
15 |
10.5 |
Market maturation, competitive dynamics |
Assumptions:
- Daxxify captures 10–20% of the botulinum toxin aesthetic market by 2025.
- Average price per treatment stabilizes at USD 650.
- Growth driven by longer-acting profile, with increasing clinician familiarity.
Market Risks and Opportunities
Risks
- Entrenched market dominance of Botox could slow Daxxify’s growth.
- Insurance reimbursement pathways are still being established.
- Clinical trial data with longer-term efficacy and safety will influence adoption.
Opportunities
- Expanding indications beyond aesthetic use (e.g., migraine, hyperhidrosis).
- Prescribing convenience may attract new users.
- Price premium justified if long-lasting effects reduce treatment frequency.
Key Takeaways
- The global botulinum toxin market is ripe for new entrants with differentiated longer-lasting products like Daxxify.
- Competitive pricing is likely to range from USD 600 to 700 per treatment.
- Revenue projections suggest significant growth potential through 2026, driven by market expansion and clinician adoption.
- Market penetration depends on clinical validation, reimbursement, and patient acceptance of less frequent treatments.
Frequently Asked Questions
1. How does Daxxify compare with Botox in terms of cost-effectiveness?
Daxxify's longer duration reduces the frequency of treatments, decreasing overall annual treatment costs. If priced at USD 650 per treatment, with a six-month duration, annual costs could be approximately USD 1,300 compared to USD 2,000–2,400 for Botox treatments over the same period.
2. What are the primary regulatory hurdles for Daxxify's market expansion?
While FDA approval covers aesthetic use in adults with glabellar lines, commercialization depends on securing reimbursement codes, insurance coverage, and adoption of new treatment protocols by clinicians.
3. What impact could emerging competitors in long-acting neurotoxins have?
Competitors developing longer-lasting formulations or combination therapies could erode Daxxify’s market share, requiring strategic differentiation and pricing adjustments.
4. Is there potential for off-label expansion of Daxxify’s uses?
Yes. Off-label uses for hyperhidrosis, migraines, and cervical dystonia could open new revenue streams, though regulatory approval would be necessary for formal indications.
5. How might pricing evolve as Daxxify gains market share?
Price reductions could occur due to increased competition and economies of scale. Early adopters may pay premium prices, but broader market acceptance could lead to more competitive pricing.
Sources
[1] MarketWatch, "Botulinum Toxin Market Size," 2022.
[2] Revance Therapeutics, "Daxxify FDA Approval," 2022.
[3] IQVIA, "Aesthetic Botulinum Toxin Market Share," 2022.
[4] Bloomberg Intelligence, "Neurotoxin Market Outlook," 2023.
